Preretinal hemorrhage as a presenting sign of idiopathic macular telangiectasia type 2

被引:3
|
作者
Osher, James M. [1 ,2 ]
Sisk, Robert A. [1 ,2 ]
Petersen, Michael R. [2 ]
机构
[1] Univ Cincinnati, Dept Ophthalmol, Cincinnati, OH USA
[2] Cincinnati Eye Inst, 1945 CEI Dr, Cincinnati, OH 45242 USA
来源
CLINICAL OPHTHALMOLOGY | 2015年 / 9卷
关键词
idiopathic macular telangiectasia; juxtafoveal telangiectasia; preretinal hemorrhage; Valsalva retinopathy;
D O I
10.2147/OPTH.S83335
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
We report three cases of idiopathic macular telangiectasia type 2 with temporally decentered preretinal hemorrhage as the presenting sign. The preretinal blood obscured the telangiectatic vessels such that the diagnosis was only evident by fluorescein angiography of the fellow eyes, which had near-normal vision. The preretinal hemorrhage was associated with Valsalva maneuver in one patient and with type 3 subretinal neovascularization in one patient. We speculate that the vascular dilations in idiopathic macular telangiectasia type 2 may increase patients' susceptibility to rupture and hemorrhage with increased venous pressure.
引用
收藏
页码:1417 / 1420
页数:4
相关论文
共 50 条
  • [41] Idiopathic macular telangiectasia
    Yannuzzi, LA
    Bardal, AMC
    Freund, KB
    Chen, KJ
    Eandi, CM
    Blodi, B
    ARCHIVES OF OPHTHALMOLOGY, 2006, 124 (04) : 450 - 460
  • [42] Idiopathic macular telangiectasia type 2 (idiopathic juxtafoveolar retinal telangiectasis type 2A, Mac Tel 2)
    Wu, Lihteh
    Evans, Teodoro
    Arevalo, J. Fernando
    SURVEY OF OPHTHALMOLOGY, 2013, 58 (06) : 536 - 559
  • [43] Suspected Neratinib Macular Toxicity Presenting As Macular Telangiectasia Type II
    Enghelberg, Moises
    Kaifee, Syeda
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (01)
  • [44] Suspected Neratinib Macular Toxicity Presenting As Macular Telangiectasia Type II
    Enghelberg, Moises
    Kaifee, Syeda
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023,
  • [45] Vitreous Hemorrhage as the Presenting Sign of Idiopathic Intracranial Hypertension
    Vosoughi, Amir R.
    Micieli, Jonathan A.
    CASE REPORTS IN OPHTHALMOLOGY, 2022, 13 (03): : 905 - 909
  • [46] Response to ‘Bevacizumab and type 1 idiopathic macular telangiectasia’
    S Ooto
    K Takayama
    N Yoshimura
    Eye, 2011, 25 : 1665 - 1665
  • [47] Response to 'Bevacizumab and type 1 idiopathic macular telangiectasia'
    Ooto, S.
    Takayama, K.
    Yoshimura, N.
    EYE, 2011, 25 (12) : 1665 - 1665
  • [48] Intravitreal bevacizumab for type 1 idiopathic macular telangiectasia
    K Takayama
    S Ooto
    H Tamura
    K Yamashiro
    A Otani
    A Tsujikawa
    N Yoshimura
    Eye, 2010, 24 : 1492 - 1497
  • [49] Intravitreal bevacizumab for type 1 idiopathic macular telangiectasia
    Takayama, K.
    Ooto, S.
    Tamura, H.
    Yamashiro, K.
    Otani, A.
    Tsujikawa, A.
    Yoshimura, N.
    EYE, 2010, 24 (09) : 1492 - 1497
  • [50] Macular telangiectasia type 2
    Issa, Peter Charbel
    Gillies, Mark C.
    Chew, Emily Y.
    Bird, Alan C.
    Heeren, Tjebo F. C.
    Peto, Tunde
    Holz, Frank G.
    Scholl, Hendrik P. N.
    PROGRESS IN RETINAL AND EYE RESEARCH, 2013, 34 : 49 - 77